First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
Recruiting · NCT07560865 · Registry updated 2026-05-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma | Disease Attributes, Disease Progression, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 | 2026-05-01 | NCT07560865 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fate Therapeutics | 7 |
| Masonic Cancer Center, University of Minnesota | 48 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Elizabeth C. Neil, MD | Minneapolis | United States | 1 |